Cardiopulmonary effects of epidurally administered xylazine in the horse.

This research was conducted to explore the effects of the alpha2 agonist, xylazine, on horse health when administered epidurally and the outcomes suggested it produced potent analgesia without observable cardiopulmonary side effects.

Objective of the Research

• The main aim of this study was to investigate whether the epidural administration of an alpha2 agonist, xylazine, could produce observable alterations in arterial blood pressure, electrocardiographic (ECG) activity, and arterial blood gas values in horses.

Research Methodology

• In order to establish the effects, the study was conducted on six horses. They were given four different treatments – epidural xylazine, intravenous xylazine, epidural lidocaine, and epidural saline.
• A carotid artery catheter was employed to measure arterial blood pressure and to collect samples for blood gas analysis. This was done both before the treatment and at various intervals thereafter. Simultaneously, other vital elements such as heart rate, arterial pressures, ECG activity and respiratory rate were also recorded at the same intervals.

Results of the Study

• The experiment found no significant differences either between the time intervals or between the individual treatments. This led to the conclusion that the xylazine administration produced potent analgesia without any measurable changes in the cardiopulmonary conditions of the horses.

Implications of the Findings

• The lack of observable side effects indicates that epidural xylazine administration could be a safe and effective method to generate analgesia in horses. It encourages further investigation into epidural xylazine as an analgesic alternative for procedures or conditions requiring alleviation of pain.